相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
100.0%
暂无批准数据
- The global wearable cardiac monitoring devices market was valued at USD 2.9 billion in 2025 and is projected to reach USD 10.3 billion by 2036, expanding at a CAGR of 12.1%. - The electrocardiography (ECG) technology segment dominated the market in 2025, accounting for approximately 62.1% of total revenue, driven by its clinical accuracy in detecting arrhythmias and atrial fibrillation. - North America held the largest regional share at 41.2% in 2025, supported by advanced healthcare infrastructure and growing adoption of remote patient monitoring solutions. - Rising prevalence of cardiovascular diseases and cardiac arrhythmias, coupled with growing demand for continuous, real-time cardiac monitoring, is the primary growth driver.
- A large-scale analysis of over 400,000 patients demonstrates that iRhythm's Zio 14-day ECG monitoring system performs consistently across Asian and non-Asian populations, with comparable wear times and arrhythmia detection rates. - Despite lower baseline prevalence of cardiovascular conditions, Asian patients showed similar atrial fibrillation detection rates (14.0% vs. 14.3%) and total arrhythmia yield (79.8% vs. 82.9%) compared to non-Asian patients. - The findings support the generalizability of long-term continuous ECG monitoring technology across diverse patient populations, addressing concerns about racial and cultural factors affecting device performance. - New research published in Heart Rhythm journal reveals that 24-48-hour Holter monitoring can miss actionable arrhythmias even in patients with daily symptoms, with 64% of daily-symptom patients requiring longer monitoring periods for detection.
- The US Patent and Trademark Office denied iRhythm Technologies' challenges to four patents covering medical technology for vital signs monitoring, with inventions dating back to 2012. - Acting Director Coke Morgan Stewart cited "settled expectations" as the key factor against reviewing patent validity, despite acknowledging several arguments favored iRhythm's position. - iRhythm was aware of one patent as early as 2013 and cited the pending application in its own patent filing, but failed to seek review earlier. - The decision highlights the importance of timing in patent challenges and the USPTO's consideration of established industry expectations in patent disputes.
- Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer to accelerate the company's expansion in precision brain mapping technology. - Under King's leadership, Turing Medical plans to launch a clinical trial of its PACE Therapy for Treatment Resistant Depression, integrating the Bullsai platform with minimally invasive neuromodulation therapy. - The company recently received FDA 510(k) clearance for its Bullsai platform, an automated cloud-based system delivering individual brain maps to support neurosurgical planning.
- iRhythm Technologies received FDA 510(k) clearance for design modifications to its Zio AT cardiac monitoring system, addressing a prior warning letter. - The clearance involves updates to the device's design and labeling, marking progress in resolving issues identified at a manufacturing facility. - iRhythm delays its FDA submission for the next-generation Zio MCT device until Q3 2025, with a commercial launch expected in 2026. - The company is enhancing its quality management system, increasing regulatory and quality staff from 20 to over 100 employees.
- iRhythm Technologies secured FDA 510(k) clearance for design modifications and labeling updates to its Zio AT mobile cardiac telemetry device, addressing concerns from a prior FDA warning letter. - The enhancements to Zio AT, which include design features and labeling updates, are intended to improve the technology for patients, physicians, and healthcare systems. - Despite the Zio AT clearance, iRhythm's plans to submit its Zio Mobile Cardiac Telemetry (MCT) system to the FDA have been delayed to the third quarter of 2025 due to remediation efforts related to Zio AT. - iRhythm reported a net loss of $46.2 million in the third quarter of 2024, but revenue increased by 18.4% to $147.5 million, with a positive full-year revenue growth projection.
- iRhythm Technologies secured FDA 510(k) clearance for design modifications and labeling updates to its Zio AT device, used for mobile cardiac telemetry. - The enhancements address concerns raised in a 2023 FDA warning letter and are slated for implementation in 2025. - The Zio AT device, paired with Zio ECG Utilization Software (ZEUS), remains commercially available in the U.S. during the modification period. - This clearance underscores iRhythm's commitment to regulatory compliance and strengthens its position in the cardiac monitoring market.
- iRhythm Technologies (IRTC) secured FDA 510(k) clearance for design updates to its Zio AT cardiac monitoring device, addressing prior regulatory concerns. - The approval marks a significant step in iRhythm's ongoing efforts to meet FDA compliance and enhance the quality and safety of its Zio AT system. - Following the announcement, iRhythm's stock experienced a surge, reflecting investor confidence in the company's progress and future prospects. - The Zio AT system, combining a wearable ECG patch with AI-powered software, is used for continuous heart monitoring for up to 14 days.
- The GUARD-AF trial, utilizing iRhythm's Zio XT patch, screened for atrial fibrillation (AF) in primary care settings, increasing new AF diagnoses to 5.0% compared to 3.3% with standard care. - Despite increased AF detection and oral anticoagulation initiation, the trial showed no significant difference in stroke hospitalization rates due to truncated enrollment and reduced statistical power. - The study confirms the feasibility of primary care-initiated, home-based cardiac monitoring for AF screening in older adults, with virtual enrollment and self-application of the Zio XT patch proving effective. - Most detected AF episodes were short and infrequent, suggesting that longer-term continuous monitoring is more effective than traditional methods for identifying paroxysmal AF.
